US medical device firm Neurametrix has struck an agreement with N-Strategy Consulting Services (NSCS) to invest in a test for neurological diseases based around typing cadence in the Asia-P
Under threat from a gene therapy from Novartis, Biogen is making the case for its drug Spinraza for the muscle wasting disease spinal muscular atrophy, with new data that it hopes persuades
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.